Monopar Therapeutics opened lower at $70.11, compared with its previous close of $71.73. In the last trading session, the stock traded between $67.12 and $75.03. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Monopar Therapeutics is now worth
$ 292.16
Giving a profit of
$ 192.16 (192.16%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$1.46 (+2.03%)
Day High
$75.03
Day Low
$67.12
Day Open
$70.11
Prev Close
$71.73
Volume
2,87,757
1W Return
1.70%
1M Return
-5.07%
3M Return
-35.78%
6M Return
11.70%
1Y Return
-12.28%
Fundamentals
Market Cap ($ Mn)
491
PE Ratio
-
PB Ratio
5.77
PEG Ratio
-
ROE
-15.58%
ROCE
-18.96%
EPS (TTM)
$-0.79
Investment Returns
1 Week
1.70%
1 Month
-5.07%
3 Months
-35.78%
6 Months
11.70%
9 Months
23.23%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
19Aug
Monopar appoints Jeffrey Kent as EVP Medical Affairs ahead of NDA
Monopar Therapeutics Inc. appointed Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. The company also announced two abstracts on ALXN1840 accepted for presentation at The Liver Meeting 2026.
2mo ago
12Aug
Monopar Therapeutics Q2 Results: EPS misses estimates, loss widens
Monopar Therapeutics Q2 results show a loss of $(0.62) per share, missing the $(0.56) estimate by 10.71%. The loss widened 77.14% YoY from $(0.35), indicating deteriorating profitability trends and underperformance against analyst expectations.
3mo ago
22Jul
Monopar begins rolling FDA submission for ALXN1840
Monopar Therapeutics Inc. has begun a rolling submission of its NDA for ALXN1840 to the FDA, having submitted the first completed sections. The drug targets Wilson disease and holds Fast Track, Orphan Drug, and Rare Pediatric Disease designations. The company has also expanded its commercial leadership team, appointing Nicole Sweeny to its Board and adding Sharon Funk and Daniel Olmstead as Senior Vice Presidents.
3mo ago
30Jun
FDA grants Rare Pediatric Disease designation to ALXN1840
Monopar Therapeutics Inc. announced that the U.S. FDA has granted Rare Pediatric Disease designation to ALXN1840 for Wilson disease, potentially allowing for a Priority Review Voucher upon NDA approval. New analyses from the Phase 3 FoCus trial demonstrated that ALXN1840 provided significant neurologic improvement and greater global clinical benefit compared to standard of care. The company plans to submit an NDA in mid-2026.
4mo ago
30Jun
BTIG raises Monopar Therapeutics target to $117
BTIG analyst Jeet Mukherjee has reaffirmed a Buy rating for Monopar Therapeutics, raising the price target to $117. This update follows previous coverage by HC Wainwright & Co., which had set a target of $105.
